CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade PharmaCyte Biotech, Inc. - PMCB CFD

    2.11
    0.94%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    Trading сonditions
    Spread 0.07
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026179 %
    Charges from full value of position ($-4.97)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026179%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003957 %
    Charges from full value of position ($0.75)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003957%
    Overnight fee time 21:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Key Stats
    Prev. Close* 2.13
    Open* 2.13
    1-Year Change* -27.8%
    Day's Range* 2.08 - 2.14
    52 wk Range 1.92-3.23
    Average Volume (10 days) 24.40K
    Average Volume (3 months) 354.19K
    Market Cap 19.73M
    P/E Ratio -100.00K
    Shares Outstanding 8.62M
    Revenue N/A
    EPS -1.00
    Dividend (Yield %) N/A
    Beta -0.17
    Next Earnings Date Mar 11, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Apr 22, 2024 2.13 0.07 3.40% 2.06 2.20 2.04
    Apr 19, 2024 2.09 0.00 0.00% 2.09 2.11 2.08
    Apr 18, 2024 2.10 0.06 2.94% 2.04 2.13 2.04
    Apr 17, 2024 2.08 -0.09 -4.15% 2.17 2.17 2.08
    Apr 16, 2024 2.13 0.05 2.40% 2.08 2.13 2.02
    Apr 15, 2024 2.09 -0.28 -11.81% 2.37 2.37 2.09
    Apr 12, 2024 2.21 0.03 1.38% 2.18 2.38 2.17
    Apr 11, 2024 2.28 0.06 2.70% 2.22 2.28 2.22
    Apr 10, 2024 2.23 0.05 2.29% 2.18 2.24 2.18
    Apr 9, 2024 2.28 -0.05 -2.15% 2.33 2.35 2.20
    Apr 8, 2024 2.37 0.03 1.28% 2.34 2.40 2.33
    Apr 5, 2024 2.40 0.00 0.00% 2.40 2.43 2.35
    Apr 4, 2024 2.44 0.00 0.00% 2.44 2.49 2.40
    Apr 3, 2024 2.48 0.11 4.64% 2.37 2.49 2.37
    Apr 2, 2024 2.39 0.02 0.84% 2.37 2.47 2.35
    Apr 1, 2024 2.40 0.07 3.00% 2.33 2.42 2.32
    Mar 28, 2024 2.35 -0.08 -3.29% 2.43 2.46 2.30
    Mar 27, 2024 2.42 0.07 2.98% 2.35 2.45 2.35
    Mar 26, 2024 2.42 -0.02 -0.82% 2.44 2.46 2.37
    Mar 25, 2024 2.44 0.01 0.41% 2.43 2.49 2.43

    PharmaCyte Biotech, Inc. Events

    Time (UTC) Country Event
    Monday, April 29, 2024

    Time (UTC)

    15:00

    Country

    US

    Event

    PharmaCyte Biotech Inc Annual Shareholders Meeting
    PharmaCyte Biotech Inc Annual Shareholders Meeting

    Forecast

    -

    Previous

    -
    Monday, July 29, 2024

    Time (UTC)

    20:00

    Country

    US

    Event

    Q4 2024 PharmaCyte Biotech Inc Earnings Release
    Q4 2024 PharmaCyte Biotech Inc Earnings Release

    Forecast

    -

    Previous

    -
    Monday, September 16, 2024

    Time (UTC)

    12:30

    Country

    US

    Event

    Q1 2025 PharmaCyte Biotech Inc Earnings Release
    Q1 2025 PharmaCyte Biotech Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2023 2022 2021 2020 2019
    Total revenue 0 0 0 0 0
    Revenue 0 0 0 0 0
    Cost of Revenue, Total
    Gross Profit
    Total Operating Expense 6.45549 4.39201 3.547 3.8264 4.10063
    Selling/General/Admin. Expenses, Total 5.98696 3.70108 2.70673 3.52517 3.64058
    Research & Development 0.46854 0.69094 0.91625 0.30122 0.46005
    Unusual Expense (Income) 0 -0.07598
    Operating Income -6.45549 -4.39201 -3.547 -3.8264 -4.10063
    Interest Income (Expense), Net Non-Operating 1.9375 0.15714 -0.00305 -0.00045
    Other, Net 0.202 -0.00428 -0.00119 -0.00004 0.0334
    Net Income Before Taxes -4.31599 -4.23916 -3.55124 -3.82689 -4.06723
    Net Income After Taxes -4.31599 -4.23916 -3.55124 -3.82689 -4.06723
    Net Income Before Extra. Items -4.31599 -4.23916 -3.55124 -3.82689 -4.06723
    Net Income -4.31599 -4.23916 -3.55124 -3.82689 -4.06723
    Income Available to Common Excl. Extra. Items -4.31599 -4.23916 -3.55124 -3.82689 -4.06723
    Income Available to Common Incl. Extra. Items -4.31599 -4.23916 -3.55124 -3.82689 -4.06723
    Diluted Net Income -4.31599 -4.23916 -3.55124 -3.82689 -4.06723
    Diluted Weighted Average Shares 19.4892 15.5217 1.44829 0.90833 0.73707
    Diluted EPS Excluding Extraordinary Items -0.22146 -0.27311 -2.45203 -4.2131 -5.5181
    Dividends per Share - Common Stock Primary Issue
    Diluted Normalized EPS -0.22146 -0.27311 -2.50449 -4.2131 -5.5181
    Total Extraordinary Items
    Jul 2023 Apr 2023 Jan 2023 Oct 2022 Jul 2022
    Total revenue 0 0 0 0 0
    Revenue 0 0 0 0 0
    Total Operating Expense 2.07533 0.90328 1.55298 2.31862 1.68061
    Selling/General/Admin. Expenses, Total 1.97084 0.81741 1.50759 2.14062 1.52134
    Research & Development 0.10448 0.08587 0.04539 0.178 0.15927
    Operating Income -2.07533 -0.90328 -1.55298 -2.31862 -1.68061
    Interest Income (Expense), Net Non-Operating 0.87588 0.72294 0.63589 0.43917 0.1395
    Other, Net -1.98385 0.05401 0.15296 -0.00106 -0.00391
    Net Income Before Taxes -3.1833 -0.12634 -0.76414 -1.88051 -1.54501
    Net Income After Taxes -3.1833 -0.12634 -0.76414 -1.88051 -1.54501
    Net Income Before Extra. Items -3.1833 -0.12634 -0.76414 -1.88051 -1.54501
    Net Income -3.1833 -0.12634 -0.76414 -1.88051 -1.54501
    Income Available to Common Excl. Extra. Items -3.50315 -0.12634 -0.76414 -1.88051 -1.54501
    Income Available to Common Incl. Extra. Items -3.50315 -0.12634 -0.76414 -1.88051 -1.54501
    Diluted Net Income -3.50315 -0.12634 -0.76414 -1.88051 -1.54501
    Diluted Weighted Average Shares 8.7781 17.802 18.9954 20.5854 20.8293
    Diluted EPS Excluding Extraordinary Items -0.39908 -0.0071 -0.04023 -0.09135 -0.07417
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.39908 -0.0071 -0.04023 -0.09135 -0.07417
    Unusual Expense (Income)
    Total Adjustments to Net Income -0.31985
    • Annual
    • Quarterly
    2023 2022 2021 2020 2019
    Total Current Assets 68.1476 85.4948 2.27524 1.03765 0.6534
    Cash and Short Term Investments 68.0399 85.4007 2.20211 0.89486 0.51525
    Cash 68.0399 85.4007 2.20211 0.89486 0.51525
    Prepaid Expenses 0.10768 0.09417 0.07313 0.14279 0.13815
    Total Assets 73.2769 90.6241 7.40423 6.16664 5.7824
    Intangibles, Net 3.54943 3.54943 3.54943 3.54943 3.54943
    Long Term Investments 1.57219 1.57219 1.57219 1.57219 1.57219
    Other Long Term Assets, Total 0.00769 0.00769 0.00737 0.00737 0.00737
    Total Current Liabilities 0.58658 0.70437 0.72478 1.0314 0.74285
    Accounts Payable 0.12828 0.20536 0.17226 0.18584 0.12189
    Accrued Expenses 0.4583 0.49901 0.55252 0.81664 0.62097
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total
    Total Liabilities 0.58658 0.70437 0.72478 1.07768 0.74285
    Total Long Term Debt 0 0 0 0.04628 0
    Total Equity 72.6903 89.9198 6.67945 5.08896 5.03955
    Common Stock 0.00216 0.00207 0.00016 0.16386 0.1186
    Additional Paid-In Capital 202.231 201.582 114.109 108.805 104.966
    Retained Earnings (Accumulated Deficit) -115.959 -111.649 -107.41 -103.858 -100.031
    Other Equity, Total -0.023 -0.01576 -0.02038 -0.02171 -0.01384
    Total Liabilities & Shareholders’ Equity 73.2769 90.6241 7.40423 6.16664 5.7824
    Total Common Shares Outstanding 16.794 20.7211 1.59008 1.09789 0.79462
    Current Port. of LT Debt/Capital Leases 0 0.02892
    Long Term Debt 0 0.04628
    Treasury Stock - Common -13.5606
    Jul 2023 Apr 2023 Jan 2023 Oct 2022 Jul 2022
    Total Current Assets 74.7512 68.1476 72.8212 77.2194 82.2558
    Cash and Short Term Investments 74.6625 68.0399 72.6402 76.9626 82.2276
    Cash 74.6625 68.0399 72.6402 76.9626 82.2276
    Prepaid Expenses 0.08865 0.10768 0.18101 0.25681 0.02815
    Total Assets 79.8805 73.2769 77.9505 82.3487 87.3851
    Intangibles, Net 3.54943 3.54943 3.54943 3.54943 3.54943
    Long Term Investments 1.57219 1.57219 1.57219 1.57219 1.57219
    Other Long Term Assets, Total 0.00769 0.00769 0.00769 0.00769 0.00769
    Total Current Liabilities 1.51802 0.58658 0.82783 1.31113 1.08936
    Accounts Payable 0.71813 0.12828 0.44594 0.86128 0.55903
    Accrued Expenses 0.48004 0.4583 0.3819 0.44986 0.53033
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases
    Total Liabilities 20.397 0.58658 0.82783 1.31113 1.08936
    Total Long Term Debt 0 0 0 0 0
    Long Term Debt
    Total Equity 59.4835 72.6903 77.1227 81.0376 86.2957
    Common Stock 0.00217 0.00216 0.00216 0.00216 0.00216
    Additional Paid-In Capital 202.231 202.231 202.231 201.601 201.593
    Retained Earnings (Accumulated Deficit) -119.462 -115.959 -115.838 -115.074 -113.194
    Other Equity, Total -0.02255 -0.023 -0.01773 -0.01517 -0.01445
    Total Liabilities & Shareholders’ Equity 79.8805 73.2769 77.9505 82.3487 87.3851
    Total Common Shares Outstanding 8.7781 16.794 18.209 20.7211 20.7501
    Treasury Stock - Common -40.0179 -13.5606 -9.25401 -5.47589 -2.09085
    Other Current Liabilities, Total 0.31985
    Other Liabilities, Total 18.879
    Redeemable Preferred Stock 16.7531
    Total Preferred Shares Outstanding 0.035
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -4.23916 -3.55124 -3.82689 -4.06723 -6.82884
    Cash From Operating Activities -4.11732 -3.33089 -2.33837 -2.87791 -5.0794
    Non-Cash Items 0.1128 0.36596 1.22117 1.02222 1.83532
    Cash Interest Paid 0.00051 0.00227 0.00045
    Changes in Working Capital 0.00904 -0.14561 0.26735 0.1671 -0.08587
    Cash From Investing Activities 0 0 0 0 0
    Other Investing Cash Flow Items, Total 0 0 0 0 0
    Cash From Financing Activities 87.3112 4.63681 2.72585 2.3425 2.68141
    Issuance (Retirement) of Stock, Net 87.3621 4.69925 2.663 2.3425 2.68141
    Issuance (Retirement) of Debt, Net -0.05081 -0.06244 0.06285
    Foreign Exchange Effects 0.00463 0.00133 -0.00787 -0.00913 -0.00645
    Net Change in Cash 83.1985 1.30725 0.37961 -0.54455 -2.40443
    Cash Taxes Paid 0.0016 0.0008 0.0008
    Jan 2023 Oct 2022 Jul 2022 Apr 2022 Jan 2022
    Net income/Starting Line -4.18966 -3.42552 -1.54501 -4.23916 -2.81645
    Cash From Operating Activities -3.50534 -2.96364 -1.08438 -4.11732 -2.92548
    Non-Cash Items 0.81355 0.01775 0.00962 0.1128 0.10406
    Cash Taxes Paid 0 0 0 0.0016 0.0016
    Cash Interest Paid 0 0 0 0.00051 0.00051
    Changes in Working Capital -0.12924 0.44413 0.45101 0.00904 -0.21309
    Cash From Investing Activities 0 0 0 0
    Other Investing Cash Flow Items, Total 0 0 0 0
    Cash From Financing Activities -9.25313 -5.47501 -2.08997 87.3112 87.3621
    Issuance (Retirement) of Stock, Net -9.25313 -5.47501 -2.08997 87.3621 87.3621
    Issuance (Retirement) of Debt, Net -0.05081 0
    Foreign Exchange Effects -0.00197 0.00058 0.0013 0.00463 0.00108
    Net Change in Cash -12.7604 -8.43807 -3.17304 83.1985 84.4377

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    PharmaCyte Biotech, Inc. Company profile

    About Pharmacyte Biotech Inc

    PharmaCyte Biotech, Inc. is a clinical-stage biotechnology company. The Company is focused on developing cellular therapies for cancer and diabetes based upon a cellulose-based live cell encapsulation technology known as Cell-in-a-Box. Cell-in-a-Box technology is used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable, non-metastatic pancreatic cancer (LAPC). The Company's lead product candidate, CypCaps is in Phase II of the clinical trials in LAPC. It also focused on developing a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes. Its product candidate for the treatment of diabetes consists of encapsulated genetically modified insulin-producing cells. The Company is also focused on the benefits of the Cell-in-a-Box technology to develop therapies for cancer that involve prodrugs based upon certain constituents of the Cannabis plant, such as cannabinoids.

    Financial summary

    BRIEF: For the nine months ended 31 January 2022, Pharmacyte Biotech Inc revenues was not reported. Net loss increased 9% to $2.8M. Higher net loss reflects General and administrative increase from $291K to $836K (expense), Legal and professional increase of 85% to $601K (expense), Director fees increase of 1% to $209K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$1.88 to -$0.74.

    Equity composition

    Common Stock $0.0001 Par, 03/11, 500M auth., 353,387,581 issd. Insiders own 9.09%. 12/03, 3 for 1 forward stock split. 03/09, Name changed from eFoodSafety.com Inc. Preferred Stock $.0001 Par, 10M auth., 5K issd.

    Industry: Pharmaceuticals (NEC)

    3960 Howard Hughes Parkway, Suite 500
    LAS VEGAS
    NEVADA 89169
    US

    Income Statement

    • Annual
    • Quarterly

    News

    We’re partnering with Newsquawk

    Filter out the noise and focus on the news that matters.

    08:32, 23 April 2024

    US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft

    The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.

    15:56, 22 April 2024

    Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

    Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

    07:56, 17 April 2024

    US Earnings Season : JP Morgan, Citigroup, Wells Fargo

    The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

    16:03, 11 April 2024

    Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

    The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

    09:22, 11 April 2024

    US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

    US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

    15:11, 9 April 2024

    How escalating geopolitical tensions are impacting oil markets

    The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.

    13:34, 4 April 2024

    People also watch

    Gold

    2,322.20 Price
    -0.220% 1D Chg, %
    Long position overnight fee -0.0193%
    Short position overnight fee 0.0111%
    Overnight fee time 21:00 (UTC)
    Spread 0.40

    ETH/USD

    3,212.54 Price
    +0.520% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 6.00

    BTC/USD

    66,404.15 Price
    -0.300% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 106.00

    XRP/USD

    0.56 Price
    -2.480% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 21:00 (UTC)
    Spread 0.01168

    Still looking for a broker you can trust?

    Join the 610,000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading